The research interests of Grzegorz S. Nowakowski, M.D., complement his clinical focus on hematology and hematologic cancers. Specifically, Dr. Nowakowski is focused on the identification of novel prognostic markers in chronic lymphocytic leukemia using phage display peptide libraries.
Dr. Nowakowski contributes to research in Mayo Clinic's Center for Individualized Medicine. He is also active in education and has been recognized for his leadership in Mayo's Hematology/Oncology Fellowship.
- Very late antigen-4 (VLA-4). Dr. Nowakowski is investigating the role of the VLA-4 adhesion receptor in resistance to chemotherapy in hematological malignancies. Correlative studies are being performed for a clinical trial of the pharmaceutical natalizumab.
- IGH mutation. A second area of focus involves work on surrogate markers of IGH mutational status in chronic lymphocytic leukemia.
- BCL2 mutation. With funding from the Center for Individualized Medicine, Dr. Nowakowski is researching somatic mutations of BCL2, with the goal of selecting the appropriate therapies for specific patients.
- Natural killer (NK) cell and large granular lymphocytic (LGL) leukemia. In a project developed through Mayo's LGL leukemia group, he is also studying the natural histories of NK and LGL leukemia.
Significance to patient care
The overarching goal of Dr. Nowakowski's research is to better understand the genetic causes of hematologic cancers, such as various types of leukemia, in order to develop personalized therapies based on the genetic profiles of individual patients.
- Program director, Advanced Hematology Fellowship, Mayo School of Graduate Medical Education, Mayo Clinic, 2013-present
- Member, International Extranodal Lymphoma Study Group, 2009-present
- Leadership Development Program, American Society of Clinical Oncology (ASCO), 2012
- Teacher of the Year, Hematology/Oncology Fellowship, Mayo Clinic, 2012
- Merit award, ASCO, 2005